Global Blood Therapeutics Inc. is a Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders.
Global Blood Therapeutics Inc. (GBT) had a good day on the market for Monday December 14 as shares jumped 5.25% to close at $42.70. About 1.66 million shares traded hands on 13,633 trades for the day, compared with an average daily volume of n/a shares out of a total float of 61.8 million. After opening the trading day at $41.29, shares of Global Blood Therapeutics Inc. stayed within a range of $44.48 to $41.16.
With today’s gains, Global Blood Therapeutics Inc. now has a market cap of $2.64 billion. Shares of Global Blood Therapeutics Inc. have been trading within a range of $87.55 and $36.50 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Global Blood Therapeutics Inc. is based out of South San Francisco, CA and has some 352 employees. Its CEO is Ted W. Love.